These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17116673)

  • 1. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
    Baba M; Miyake H; Wang X; Okamoto M; Takashima K
    Antimicrob Agents Chemother; 2007 Feb; 51(2):707-15. PubMed ID: 17116673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.
    Anastassopoulou CG; Marozsan AJ; Matet A; Snyder AD; Arts EJ; Kuhmann SE; Moore JP
    PLoS Pathog; 2007 Jun; 3(6):e79. PubMed ID: 17542646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
    Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
    J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.
    Trkola A; Kuhmann SE; Strizki JM; Maxwell E; Ketas T; Morgan T; Pugach P; Xu S; Wojcik L; Tagat J; Palani A; Shapiro S; Clader JW; McCombie S; Reyes GR; Baroudy BM; Moore JP
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):395-400. PubMed ID: 11782552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.
    Kanbara K; Sato S; Tanuma J; Tamamura H; Gotoh K; Yoshimori M; Kanamoto T; Kitano M; Fujii N; Nakashima H
    AIDS Res Hum Retroviruses; 2001 May; 17(7):615-22. PubMed ID: 11375057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
    Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
    J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
    Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
    J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
    Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
    J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.
    Baba M; Miyake H; Okamoto M; Iizawa Y; Okonogi K
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):935-41. PubMed ID: 10890354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
    Tremblay CL; Giguel F; Guan Y; Chou TC; Takashima K; Hirsch MS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3483-5. PubMed ID: 16048964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
    Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.